431 related articles for article (PubMed ID: 23846019)
1. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Bamber L; Wang MY; Prins MH; Ciniglio C; Bauersachs R; Lensing AW; Cano SJ
Thromb Haemost; 2013 Oct; 110(4):732-41. PubMed ID: 23846019
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Prins MH; Bamber L; Cano SJ; Wang MY; Erkens P; Bauersachs R; Lensing AW
Thromb Res; 2015 Feb; 135(2):281-8. PubMed ID: 25483215
[TBL] [Abstract][Full Text] [Related]
3. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
4. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
[TBL] [Abstract][Full Text] [Related]
5. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
van Bellen B; Bamber L; Correa de Carvalho F; Prins M; Wang M; Lensing AW
Curr Med Res Opin; 2014 May; 30(5):829-37. PubMed ID: 24432872
[TBL] [Abstract][Full Text] [Related]
6. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Cohen AT; Dobromirski M
Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
[TBL] [Abstract][Full Text] [Related]
7. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Burness CB; Perry CM
Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
[TBL] [Abstract][Full Text] [Related]
10. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
11. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
Prandoni P; Prins MH; Cohen AT; Müller K; Pap ÁF; Tewes MC; Lensing AW
Acad Emerg Med; 2015 Feb; 22(2):142-9. PubMed ID: 25676529
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
16. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of acute deep vein thrombosis with new oral anticoagulant rivaroxaban: the first experience].
Schastlivtsev IV; Lobastov KV; Barinov VE; Boiarintsev VV
Khirurgiia (Mosk); 2014; (6):61-6. PubMed ID: 25042194
[TBL] [Abstract][Full Text] [Related]
18. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
20. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]